Today on Drug Discovery & Development
Novavax’s COVID-19 vaccine demonstrates 90% efficacy
Novavax (NSDQ:NVAX) announced today that its COVID-19 vaccine demonstrated 90.4% efficacy in protecting against COVID-19. Gaithersburg, Md.–based Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall as it met the primary endpoint in the Prevent-19 pivotal Phase 3 trial. According to a news release, the study…
Top J&J exec moves to Moderna
Moderna (NSDQ:MRNA) announced today that former Johnson & Johnson executive Dr. Paul Burton will join as chief medical officer. Cambridge, Mass.-based Moderna said in a news release that Burton assumes the role of CMO effective July 6, 2021, and he will serve on the company’s executive committee and report to CEO Stéphane Bancel. “Paul’s extensive…
Drug Discovery and Development See More >
Building a new foundation for oncology clinical trials
The COVID-19 pandemic disrupted oncology clinical trials, and drug developers and regulators, including the FDA, continue to look for ways to catalyze clinical trial innovation. The FDA has been “vigilant as they always are to make sure that there is strong science, but they are much more open both in study design, alternative execution methods…
Sponsored Content See More >
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
Unraveling the promise of genetics for treating progressive illness
For almost every major common disease, researchers have less understanding of the severe forms than milder cases. And as a result, people with severe forms of diseases often have few treatment options available. Thus, the significant unmet medical need for many diseases ranging from multiple sclerosis to Alzheimer’s is to halt disease progression and treat severe…
Vertex Pharmaceuticals wins FDA fast track designation for its cell-based diabetes treatment
How to build a foundation for the next phase of Alzheimer’s disease research
Why Genuity and Emory are partnering on neurodegenerative disease research
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Infectious Disease See More >
Novavax’s COVID-19 vaccine demonstrates 90% efficacy
Novavax (NSDQ:NVAX) announced today that its COVID-19 vaccine demonstrated 90.4% efficacy in protecting against COVID-19. Gaithersburg, Md.–based Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall as it met the primary endpoint in the Prevent-19 pivotal Phase 3 trial. According to a news release, the study…
Oncology See More >
Daiichi Sankyo’s valemetostat fares well in lymphoma and leukemia study
Valemetostat, a potential first-in-class drug from Daiichi Sankyo, led to durable tumor response in patients with peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL) in a Phase 1 study. The company presented highlights from the trial at the European Hematology Association (EHA) 2021 Virtual Congress today. In the study, the objective response rate was…
